Screening for Hepatitis D Virus in HIV and HBV Coinfected Individuals
Universal Screening for Hepatitis Delta Virus (HDV) in Individuals Living with HIV/HBV Coinfection and HBV-related HCC
This study looks at how common hepatitis delta virus is in people who have both HIV and hepatitis B in Hong Kong to better understand their health needs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06889805 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and disease burden of hepatitis delta virus (HDV) among individuals who are coinfected with HIV and hepatitis B virus (HBV) in Hong Kong. It will involve a cross-sectional analysis of individuals living with these infections, focusing on those with chronic HBV and related health complications. The study seeks to fill the gap in existing data regarding HDV in this specific population, which is crucial for understanding the overall impact of these infections.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 and older who are coinfected with HIV and chronic hepatitis B.
Not a fit: Patients who do not have HIV or chronic hepatitis B infection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the prevalence of HDV, leading to better management and treatment strategies for affected patients.
How similar studies have performed: While there is limited data on HDV in this specific population, similar studies on viral coinfections have shown the importance of understanding disease burden, suggesting potential for impactful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND 2. Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND 3. Aged 18 years old or above. 4. Written or verbal consent obtained Exclusion Criteria: 1. Refusal to consent 2. Age \< 18 years
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Lai Hung Grace Wong — Chinese University of Hong Kong
- Study coordinator: Angel Chim
- Email: angelchim@cuhk.edu.hk
- Phone: +85235054205
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.